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PCLINICAL RESEARCH Acute Coronary Syndromes
Outcomes Following Pre-Operative Clopidogrel
Administration in Patients With Acute Coronary
Syndromes Undergoing Coronary Artery Bypass Surgery
The ACUITY (Acute Catheterization
and Urgent Intervention Triage strategY) Trial
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Objectives This study sought to evaluate the impact of upstream clopidogrel in patients with non–ST-segment elevation
acute coronary syndromes (NSTE-ACS) requiring coronary artery bypass grafting (CABG) from the ACUITY (Acute
Catheterization and Urgent Intervention Triage strategY) trial.
Background Despite benefits of clopidogrel in patients with NSTE-ACS undergoing percutaneous coronary intervention, this
agent is often not administered upstream (before angiography) as recommended by the American College of
Cardiology/American Heart Association guidelines because of potential bleeding in the minority of patients who
require CABG.
Methods The ACUITY trial enrolled 13,819 patients with NSTE-ACS undergoing early invasive management. The timing of
clopidogrel initiation was per investigator discretion. A 5-day washout period before CABG was recommended for
patients having received clopidogrel.
Results Of 13,819 patients enrolled, 1,539 (11.1%) underwent CABG before discharge. Clopidogrel-exposed patients had
a longer median duration of hospitalization (12.0 days vs. 8.9 days, p  0.0001), but fewer adverse composite
ischemic events (death, myocardial infarction, or unplanned revascularization) at 30 days; 12.7% vs. 17.3%, p 
0.01), with nonsignificantly different rates of non–CABG-related major bleeding (3.4% vs. 3.2%, p  0.87) and
post-CABG major bleeding (50.3% vs. 50.9%, p  0.83) compared with those patients not administered clopi-
dogrel. By multivariable analysis, clopidogrel use before CABG was an independent predictor of reduced 30-day
composite ischemia (odds ratio: 0.67, 95% confidence interval: 0.48 to 0.92, p  0.001) but not of increased
post-CABG major bleeding (odds ratio: 0.98, 95% confidence interval: 0.80 to 1.19, p  0.80).
Conclusions Clopidogrel administration before catheterization in patients with NSTE-ACS requiring CABG is associated with signifi-
cantly fewer 30-day adverse ischemic events without significantly increasing major bleeding, compared to withholding
clopidogrel until after angiography. These findings support the American College of Cardiology/American Heart Asso-
ciation guidelines for upstream clopidogrel administration in all NSTE-ACS patients, including those who subsequently
undergo CABG. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes [ACS]; NCT00093158).
(J Am Coll Cardiol 2009;53:1965–72) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.006School of Medicine, New York, New York; ¶Lehigh Valley Hospital, Allentown,
Pennsylvania; #Mayo Clinic, Rochester, Minnesota; **Duke University Medical
Center, Durham, North Carolina; ††Auckland City Hospital, Auckland, Newrom the *University of California Los Angeles and the Greater Los Angeles VA
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orth Carolina; ‡Columbia University Medical Center and The Cardiovascular
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Outcomes After Pre-Operative Clopidogrel Use May 26, 2009:1965–72The American College of Cardi-
ology (ACC) and American Heart
Association (AHA) guidelines for
patients presenting with non–ST-
segment elevation (NSTE) acute
coronary syndromes (ACS) rec-
ommend early/upstream dual an-
tiplatelet therapy with aspirin
and either clopidogrel or a glyco-
protein (GP) IIb/IIIa inhibitor
(1,2). However, for patients in
whom an early invasive manage-
ment strategy is planned, many
physicians withhold upstream
clopidogrel therapy until after
coronary angiography because
of potential bleeding complica-
tions that might occur in the
approximately 10% of patients
who require coronary artery bypass
grafting (CABG) (3–5). The im-
pact of upstream clopidogrel ad-
ministration for patients with
NSTE-ACS undergoing CABG
has not been studied in a con-
temporary randomized trial. Sev-
eral, mostly small, retrospective,
nonrandomized studies have re-
ported higher transfusion and re-
exploration rates for patients un-
dergoing CABG after exposure
o clopidogrel (6–11). Based on these limited data, the
ociety of Thoracic Surgeons (STS) and ACC/AHA
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Abbreviations
and Acronyms
ACC  American College of
Cardiology
ACS  acute coronary
syndromes
AHA  American Heart
Association
CABG  coronary artery
bypass grafting
CI  confidence interval
CPK  creatine
phosphokinase
GP  glycoprotein
MI  myocardial infarction
NACE  net adverse
clinical events
NSTE  non–ST-segment
elevation
NSTEMI  non–ST-segment
elevation myocardial
infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
STS  Society of Thoracic
Surgeons
UFH  unfractionated
heparin
ULN  upper limit of normalm
Manuscript received December 9, 2008; revised manuscript received February 23,
009, accepted March 3, 2009.uidelines recommend cessation of clopidogrel for 5 to 7
ays in patients undergoing nonemergent CABG (1,2,12).
oreover, although upstream dual-antiplatelet therapy re-
uces ischemic end points in patients with NSTE-ACS
reated medically or with percutaneous coronary interven-
ion (PCI) (13,14), whether administration of platelet
nhibitors before CABG improves clinical outcomes has not
een extensively studied.
See page 1973
In the present analysis, we examined the subgroup of
atients enrolled in the ACUITY (Acute Catheterization
nd Urgent Intervention Triage strategY) trial (a large,
rospective, randomized trial of 13,819 patients with
oderate- and high-risk NSTE-ACS undergoing early
nvasive management) who after diagnostic angiography
ere subsequently managed by CABG (4). We sought to
valuate: 1) the effect of clopidogrel administration before
urgery on ischemic and bleeding outcomes and length of
tay; and 2) the impact of clopidogrel administration before
ABG and the timing of CABG on clinical outcomes in
he surgical population.
ethods
tudy design and analysis. The study design and principal
esults from the ACUITY trial have been published (4,15).
riefly, 13,819 patients with NSTE-ACS undergoing an
arly invasive management strategy were randomly assigned
o 1 of 3 antithrombotic regimens: heparin (unfractionated
eparin [UFH] or enoxaparin) plus a GP IIb/IIIa inhibitor
the control group), bivalirudin plus a GP IIb/IIIa inhibitor,
r bivalirudin monotherapy. The study was approved by the
nstitutional review board or ethics committee at each
articipating center, and all patients signed written, in-
ormed consent.
Coronary angiography was required within 72 h of
andomization with subsequent triage to PCI, CABG, or
edical management per standard of care. Aspirin (300 to
25 mg orally or 250 to 500 mg intravenously) was
dministered before angiography. Clopidogrel dosing and
iming were left to the discretion of each investigator, but in
atients undergoing PCI, the protocol required 300 mg
lopidogrel in all cases no later than 2 h after PCI.
lopidogrel 75 mg daily was recommended for 1 year in all
atients after PCI, and aspirin 75 to 325 mg daily indefi-
itely. The exact first dose of clopidogrel and the total
uration of that dose were recorded in the case report
orm only for those patients receiving the initial dose of
lopidogrel after randomization; this information was not
vailable for patients maintained on clopidogrel before
dmission. For patients who received clopidogrel before
ngiography and in whom CABG was subsequently
lanned, a 5-day clopidogrel washout period was recom-
ended before surgery.
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May 26, 2009:1965–72 Outcomes After Pre-Operative Clopidogrel UseAll patients undergoing CABG received UFH as the
nticoagulant, with dosing per standard institutional prac-
ice. For patients randomized to bivalirudin, the drug was to
e discontinued for at least 1 h before surgery. Patients
andomized to UFH continued on the drug per standard
ractice. For patients receiving enoxaparin and undergoing
lective CABG, the drug was to be stopped for at least 8 h
efore surgery. For those patients randomized to enoxaparin
equiring emergency CABG, the drug was to be stopped for
t least 8 h before surgery if possible.
The primary analysis of interest was the determination of
0-day and 1-year outcomes in patients exposed to clopi-
ogrel before CABG versus those in whom CABG was
erformed without clopidogrel exposure. Patients were de-
ned as exposed to clopidogrel before CABG if they were
aking clopidogrel on a regular basis before hospitalization
r received clopidogrel in-hospital at any time before
ABG. As a secondary analysis, in the subset of patients
ho received clopidogrel before surgery, we assessed out-
omes in patients who underwent CABG within 5 days of
he last dose of clopidogrel (the early group) versus those
ho had CABG more than 5 days after the last dose of
lopidogrel (the late group). If clopidogrel was administered
fter randomization, the exact time of the last dose was used
s the stop time. If the last dose of clopidogrel was
dministered before randomization, the time of randomiza-
ion was used as the stop time. If clopidogrel exposure was
efore hospitalization, stop time was counted as the same
ay as hospitalization.
nd points. End points assessed in the present analyses
ncluded the 3 ACUITY trial 30-day primary end points:
) composite ischemia (defined as death from any cause,
yocardial infarction [MI], or unplanned revascularization
or ischemia); 2) non–CABG-related major bleeding (de-
ned as intracranial or intraocular bleeding, access site
emorrhage requiring intervention, 5 cm diameter hema-
oma, reduction in hemoglobin of 4 g/dl without or 3
/dl with an overt bleeding source, reoperation for bleeding,
r blood product transfusion); and 3) net adverse clinical
vents (NACE) (composite ischemia or non–CABG-
elated major bleeding). An MI before angiography in
atients without non–ST-segment elevation myocardial in-
arction (NSTEMI) at admission was defined as any eleva-
ion of troponin or creatine phosphokinase (CPK)-MB
reater than the upper limit of normal (ULN) (or CPK
ULN in the absence of MB determination). In patients
ith NSTEMI at presentation, in whom the elevated
roponin or CPK-MB (or CPK) levels were documented to
e decreasing or had returned to normal, diagnosis of a
econd infarction required: 1) a new elevation of troponin or
PK-MB ULN (or CPK ULN in the absence of MB
etermination) if the troponin or CPK-MB (or CPK) level
ad returned to ULN; or 2) an increase by 50% above
he previous nadir level if the troponin or CPK-MB (or
PK) level had not returned to ULN. In patients with
STEMI at presentation, in whom the peak troponin or ePK-MB (or CPK) had not yet been reached, diagnosis of
second infarction required: 1) recurrent chest pain 30
in; or 2) new electrocardiographic changes consistent with
I; and 3) the next troponin or CPK-MB (or CPK) level
easured approximately 8 to 12 h after the event was
levated by at least 50% above the previous level. In patients
ndergoing CABG, diagnosis of MI required: 1) any
PK-MB 10 ULN (or CPK 10 ULN in the
bsence of MB determination) within 24 h of CABG and
ncreased at least 50% over the most recent pre-CABG
evels; or 2) any CPK-MB5 ULN (or CPK5 ULN
n the absence of MB determination) within 24 h of CABG
nd increased at least 50% over the most recent pre-CABG
evels and new, significant (0.04 s) Q waves in 2
ontiguous electrocardiograph leads.
Composite ischemia and mortality were measured up to 1
ear, whereas bleeding end points were assessed up to 30
ays. Data on adverse events specific to CABG were also
ollected and analyzed, including the rates of post-CABG
ajor bleeding (classified similarly to non–CABG-related
ajor bleeding but occurring in the post-CABG period),
ost-CABG transfusions, reoperation for bleeding, and
4-h chest tube output. Data on length of hospital stay were
lso collected. All primary end points were adjudicated by a
linded clinical events committee, with the exception of the
ABG-related bleeding end points.
tatistical analysis. Continuous variables were summa-
ized by means, standard deviation, medians, interquartile
anges, and minimum and maximum values. Categorical
ariables were summarized by frequencies and percentages.
issing or unknown data values were not imputed unless
therwise specified, and denominators of categorical vari-
bles excluded unknown or missing values. Categorical
ariables were compared using chi-square statistics. A non-
arametric Wilcoxon rank sum test was used for comparison
f continuous variables. Pairwise comparisons among 3
roups were made without adjustment for multiple compar-
sons. A value of p  0.05 was considered statistically
ignificant.
Multivariable logistic regression analysis was performed
o adjust for potential baseline differences between groups.
ovariates were selected using a forward stepwise procedure
rom a large number of candidate variables using p  0.15
s the criterion for entry into the model and p  0.10 to
llow a variable to stay in the model. Candidate variables
ncluded actual procedure performed, age 65 years, ane-
ia, baseline creatine kinase-MB/troponin elevation, base-
ine creatinine clearance 60 ml/min, electrocardiographic
hanges at baseline, diabetes mellitus, sex, hyperlipidemia,
ypertension, pre-CABG clopidogrel use, prior MI, prior
CI, prior CABG, randomization to bivalirudin versus
eparin plus GP IIb/IIIa inhibitor, and enrollment in the
.S. The adjusted p values, odds ratios (ORs), and corre-
ponding 2-sided 95% confidence intervals (CIs) were
omputed for these variables. Separate models were run to
valuate predictors of 30-day composite ischemia, non–
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Outcomes After Pre-Operative Clopidogrel Use May 26, 2009:1965–72ABG-related major bleeding, and post-CABG major
leeding. Pre-CABG clopidogrel use, the primary interest
ariable, was forced into each of the models. All statistical
nalyses were performed using SAS version 8.2 (SAS
nstitute Inc., Cary, North Carolina).
esults
tudy population. Of the 13,819 NSTE-ACS patients
nrolled in the ACUITY trial, 1,539 patients (11.1%)
nderwent CABG. Of these, 1,298 patients (84.3%) had
n-pump surgery, 196 (12.7%) had off-pump surgery, and
7 (2.4%) had off-pump surgery that was converted intra-
peratively to on-pump surgery. Patients who received
iclopidine (n  19) were excluded from the analysis. The
tudy cohort thus consists of 1,520 patients with NSTE-
CS undergoing CABG after diagnostic angiography.
ollow-up at 1 year was obtained in 91.8% (1,396 of 1,520)
f patients.
mpact of clopidogrel administration before CABG. Of
he 1,520 study patients, 773 (50.9%) received clopidogrel
efore CABG and 747 (49.1%) did not. Of the 773 patients
xposed to clopidogrel, 73 received it before hospitalization
nly, 157 received it before hospitalization and in hospital,
nd 543 received clopidogrel in hospital only. Baseline
haracteristics were similar between the 2 groups (Table 1),
lthough patients who received clopidogrel more often had
history of hypertension (p  0.03). The incidence of
lopidogrel use in patients undergoing CABG was signifi-
antly higher in patients enrolled outside of the U.S.
non-U.S.) as opposed to U.S. patients (70.3% vs. 36.1%,
 0.0001). The mean ( SD) time from coronary angiog-
aphy to surgery was 5.0  5.3 days in the clopidogrel-
emographic and Baseline Characteristics of Patients Undergoing
Table 1 Demographic and Baseline Characteristics of Patients
Clopidogrel Before CA
(n  773)
Age, yrs, median (range) 65 (33–87)
Female 180/773 (23.3)
Diabetes 263/773 (34.0)
Renal insufficiency* 132/730 (18.1)
Hypertension 537/773 (69.5)
Current smoker 213/773 (27.6)
Prior MI 197/773 (25.5)
Prior PCI 188/773 (24.3)
Prior CABG 44/773 (5.7)
High risk† 644/751 (85.8)
Elevated cardiac biomarkers 533/723 (73.7)
ECG changes 399/773 (51.6)
Aspirin use before CABG 759/773 (98.2)
GP IIb/IIIa inhibitor use before CABG 317/773 (41.0)
Discharged on aspirin 706/773 (91.3)
Discharged on clopidogrel 507/773 (65.6)
Non-U.S. 461/773 (59.6)
alues are presented as n/N (%) unless otherwise specified. *Renal insufficiency was defined as
levation or ST-segment deviation.
CABG  coronary artery bypass grafting; ECG  electrocardiographic; GP  glycoprotein; MI  myocareated group versus 3.0 4.1 days in the non–clopidogrel-
reated group (p  0.0001). Patients exposed to clopidogrel
efore CABG also had a significantly longer total median
uration of hospitalization (12.0 days vs. 8.9 days, p 
.0001), because of longer median pre-CABG (4.2 days vs.
.5 days, p  0.0001) and post-CABG (6.9 days vs. 5.8
ays, p  0.0001) lengths of stay.
Unadjusted 30-day results showed significantly lower
ates of composite ischemia in patients who received com-
ared with those who did not receive clopidogrel before
urgery (12.7% vs. 17.3%, respectively, p  0.01) because of
ignificantly fewer MIs in clopidogrel-treated patients (8.8%
s. 14.5%, p  0.0006), with comparable rates of death and
nplanned revascularization (Table 2). The rates of non–
ABG-related major bleeding were also similar in patients
ho did and did not receive clopidogrel before CABG
3.4% vs. 3.2%, respectively, p  0.87). As a result, NACE
ccurred less frequently in patients exposed to clopidogrel
efore CABG (15.4% vs. 19.4%, p  0.04). The incidence
f post-CABG major bleeding (50.3% vs. 50.9%, p 0.83),
lood transfusion (38.4% vs. 38.4%, p  1.00), reoperation
or bleeding (1.3% vs. 1.3%, p  0.94), and 24-h chest tube
utput (590 ml vs. 551 ml, p  0.52) were similar in those
atients who did and did not receive clopidogrel before
ABG, respectively (Table 2). When the definition of
lopidogrel exposure was changed to those who received
n-hospital clopidogrel but not before hospitalization
n  543) or those who received in-hospital clopidogrel
egardless of receiving clopidogrel before hospitalization
n  700), the above analysis showed a similar significant
eduction in 30-day ischemic outcomes in those exposed to
lopidogrel without a significant increase in non–CABG-
According to Clopidogrel Exposure Before Surgery
rgoing CABG According to Clopidogrel Exposure Before Surgery
No Clopidogrel Before CABG
(n  747) p Value
64 (35–90) 0.66
173/747 (23.2) 0.95
254/747 (34.0) 1.00
136/696 (19.5) 0.48
475/747 (63.6) 0.03
209/747 (28.0) 0.19
168/747 (22.5) 0.13
150/747 (20.1) 0.07
28/747 (3.7) 0.20
610/709 (86.0) 0.88
511/696 (73.4) 0.90
353/747 (47.3) 0.09
727/747 (97.3) 0.25
308/747 (41.2) 0.93
695/747 (93.0) 0.22
110/747 (14.7) 0.0001
195/747 (26.1) 0.0001
ed creatinine clearance 60 ml/min. †High risk was defined as: creatine kinase-MB or troponinCABG
Unde
BG
calculatrdial infarction; PCI  percutaneous coronary intervention.
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May 26, 2009:1965–72 Outcomes After Pre-Operative Clopidogrel Useelated major bleeding (data not shown). At 1 year, the rates
f composite ischemia and death were not significantly
ifferent between the 2 groups (Table 2).
By multivariable analysis, clopidogrel administration be-
ore CABG was an independent predictor of freedom from
omposite ischemia at 30 days (OR: 0.67, 95% CI: 0.48 to
.92, p  0.001) (Fig. 1), with a nonsignificant trend
resent for reduced 1-year adverse ischemic events in
lopidogrel-exposed CABG patients (OR: 0.77, 95% CI:
.59 to 1.01, p  0.06). Other variables identified as
linical Outcomes at 30 Days and 1 Year in Patients Undergoing C
Table 2 Clinical Outcomes at 30 Days and 1 Year in Patients U
Clopidogrel Before
(n  773)
30-day clinical outcomes
Net adverse clinical events 119 (15.4)
Composite ischemia 98 (12.7)
Death 30 (3.9)
Myocardial infarction 68 (8.8)
Unplanned revascularization 16 (2.1)
Non–CABG-related major bleeding 26 (3.4)
All major bleeding, post-CABG 389 (50.3)
Transfusion 297 (38.4)
Reoperation for bleeding 10 (1.3)
24-h chest tube output, ml, median (IQR) 590 (350–86
Total length of stay, days, median 12.0
Pre-CABG length of stay 4.2
Post-CABG length of stay 6.9
1-year clinical outcomes
Composite ischemia 142 (18.4)
Death 54 (7.0)
alues are presented as n (%) unless otherwise specified.
IQR  interquartile range; other abbreviations as in Table 1.
Figure 1 Predictors of Composite Ischemia
Multivariable predictors of 30-day composite ischemia, major bleeding not related
model, with pre-CABG clopidogrel use forced in, was run for each of the outcomesndependent predictors of higher 30-day composite ischemia
ncluded hypertension and prior CABG. The geographic
ocation of patients (U.S. vs. non-U.S.) was not an indepen-
ent predictor of 30-day composite ischemia. Interaction
nalysis for rates of clopidogrel exposure in U.S. versus
on-U.S. population showed nonsignificant results. Clopi-
ogrel use before CABG was not independently correlated
ith non–CABG-related major bleeding (OR: 1.04, 95% CI:
.59 to 1.87, p  0.87) or with post-CABG major bleeding
OR: 0.98, 95% CI: 0.80 to 1.19, p  0.80) (Fig. 1).
According to Clopidogrel Exposure Before Surgery
going CABG According to Clopidogrel Exposure Before Surgery
No Clopidogrel Before CABG
(n  747) p Value
145 (19.4) 0.04
129 (17.3) 0.01
29 (3.9) 1.00
108 (14.5) 0.0006
7 (0.9) 0.07
24 (3.2) 0.87
380 (50.9) 0.83
287 (38.4) 1.00
10 (1.3) 0.94
551 (350–880) 0.52
8.9 0.0001
2.5 0.0001
5.8 0.0001
160 (21.4) 0.14
46 (6.2) 0.52
onary artery bypass graft (CABG), and post-CABG major bleeding. A separate
confidence interval; OR  odds ratio; PCI  percutaneous coronary intervention.ABG
nder
CABG
0)to cor
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Outcomes After Pre-Operative Clopidogrel Use May 26, 2009:1965–72mpact of CABG timing after clopidogrel exposure. Of
he 773 patients who received clopidogrel before CABG,
24 (67.8%) underwent CABG 5 days after the last
lopidogrel dose (the early group) and 249 (32.2%) patients
nderwent CABG 5 days after the last clopidogrel dose
the late group). Baseline characteristics of patients under-
oing early versus late CABG were generally comparable
ith each other and with those who did not receive
lopidogrel (Table 3). Hypertension and prior PCI before
dmission were more common in patients exposed to
lopidogrel who underwent early CABG compared with
hose who were not exposed to clopidogrel.
Compared with patients who did not receive clopidogrel
efore CABG, those patients who received clopidogrel and
emographic and Baseline Characteristics of Patients by Use and
Table 3 Demographic and Baseline Characteristics of Patients
Clopidogrel Use and Early CABG
(<5 days) (n  524)
Clopidog
(>5
Age, yrs, median (range) 65 (35–87)
Female 131/524 (25.0)
Diabetes 179/524 (34.2)
Renal insufficiency§ 93/491 (18.9)
Hypertension 370/524 (70.6)
Current smoker 147/524 (28.1)
Prior MI 132/524 (25.2)
Prior PCI 133/524 (25.4)
Prior CABG 34/524 (6.5)
Discharged on aspirin 233/249 (93.6)
Discharged on clopidogrel 166/249 (66.7)
High risk 430/506 (85.0)
Elevated cardiac biomarkers 354/487 (72.7)
ECG changes 264/524 (50.4)
alues are presented as n/N (%) unless otherwise specified. *p value for the comparison of clopid
o clopidogrel. ‡p value for comparison of clopidogrel use and late CABG versus no clopidogrel. §
s: creatine kinase-MB or troponin elevation or ST-segment deviation.
Abbreviations as in Table 1.
linical Outcomes by Use and Timing of Clopidogrel in Relation to
Table 4 Clinical Outcomes by Use and Timing of Clopidogrel in
Clopidogrel Use and Early CABG
(<5 days) (n  524)
30-day clinical outcomes
Net adverse clinical events 87 (16.6)
Composite ischemia 76 (14.5)
Death 24 (4.6)
Non–CABG-related major bleeding 15 (2.9)
Major bleeding, post-CABG 273 (52.1)
Transfusion 219 (41.8)
Reoperation for bleeding 8 (1.5)
24-h chest tube output, ml, median (IQR) 600 (360–860)
Total length of stay, days, median 10.4
Pre-CABG length of stay 2.9
Post-CABG length of stay 6.9
1-year clinical outcomes
Composite ischemia 105 (20.0)
Death 42 (8.0)
alues are presented as n (%) unless otherwise specified. *p value for the comparison of clopidog
lopidogrel. ‡p value for comparison of clopidogrel use and late CABG versus no clopidogrel.
Abbreviations as in Tables 1 and 2.nderwent CABG within 5 days of the last clopidogrel dose
ad comparable rates of ischemia at 30 days and 1 year, with
o significant differences in any measure of bleeding either
efore or after CABG (Table 4). In contrast, patients
xposed to clopidogrel who underwent CABG 5 days
fter the last clopidogrel dose had significantly lower 30-day
ates of composite ischemia (8.8% vs. 17.3%, p  0.001),
ACE (12.9% vs. 19.4%, p  0.02), and transfusion
31.3% vs. 38.4%, p  0.04), as well as lower rates of 1-year
omposite ischemia (14.9% vs. 21.4%, p  0.02) compared
ith those who were not exposed to clopidogrel (Table 4),
ith no increase in any measure of pre- or post-CABG
leeding. However, the pre-CABG and total length of
ospital stay were significantly longer in patients undergo-
g of Clopidogrel in Relation to CABG
se and Timing of Clopidogrel in Relation to CABG
e and Late CABG
) (n  249) p Value*
No Clopidogrel
(n  747) p Value† p Value‡
33–86) 0.63 64 (35–90) 0.57 0.99
49 (19.7) 0.10 173/747 (23.2) 0.45 0.25
49 (33.7) 0.94 254/747 (34.0) 0.99 0.96
39 (16.3) 0.39 136/696 (19.5) 0.80 0.27
49 (67.1) 0.32 475/747 (63.6) 0.03 0.53
49 (26.5) 0.72 209/747 (28.0) 0.15 0.63
49 (26.1) 0.60 168/747 (22.5) 0.13 0.47
49 (22.1) 0.54 150/747 (20.1) 0.03 0.70
49 (4.0) 0.30 28/747 (3.7) 0.08 0.83
24 (90.3) 0.13 695/747 (93.0) 0.07 0.77
24 (65.1) 0.66 110/747 (14.7) 0.0001 0.0001
45 (87.3) 0.38 610/709 (86.0) 0.61 0.61
36 (75.8) 0.37 511/696 (73.4) 0.78 0.46
49 (54.2) 0.32 353/747 (47.3) 0.27 0.06
se and early versus late CABG. †p value for comparison of clopidogrel use and early CABG versus
nsufficiency was defined as calculated creatinine clearance 60 ml/min. High risk was defined
tion to CABG
ogrel Use and Late CABG
>5 days) (n  249) p Value*
No Clopidogrel
(n  747) p Value† p Value‡
32 (12.9) 0.18 145 (19.4) 0.20 0.02
22 (8.8) 0.03 129 (17.3) 0.19 0.001
6 (2.4) 0.14 29 (3.9) 0.54 0.27
11 (4.4) 0.26 24 (3.2) 0.72 0.37
116 (46.6) 0.15 380 (50.9) 0.67 0.24
78 (31.3) 0.005 287 (38.4) 0.23 0.04
2 (0.8) 0.41 10 (1.3) 0.78 0.50
550 (320–850) 0.37 551 (350–880) 0.32 0.82
15.6 0.0001 8.9 0.0001 0.0001
8.9 0.0001 2.5 0.58 0.0001
6.8 0.009 5.8 0.0001 0.15
37 (14.9) 0.08 160 (21.4) 0.55 0.02
12 (4.8) 0.10 46 (6.2) 0.20 0.43
and early versus late CABG. †p value for comparison of clopidogrel use and early CABG versus noTimin
by U
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May 26, 2009:1965–72 Outcomes After Pre-Operative Clopidogrel Useng late CABG compared with those in whom no clopi-
ogrel was administered or in whom CABG was performed
ithin 5 days of clopidogrel administration (Table 4).
iscussion
he major findings from this analysis of 1,520 patients with
oderate- and high-risk NSTE-ACS in whom CABG was
erformed for revascularization after diagnostic angiography
re that: 1) compared with patients who did not receive
lopidogrel before CABG, those who received clopidogrel
t any time before CABG had significantly reduced rates of
omposite ischemia and MI at 30 days with comparable
ates of pre- and post-CABG major bleeding; 2) multiva-
iable analysis identified clopidogrel administration before
ABG as an independent predictor of reduced 30-day
omposite ischemia (OR: 0.67, p  0.001); 3) compared
ith patients who did not receive clopidogrel before
ABG, the rates of post-CABG major bleeding and
ransfusion were not significantly increased in patients who
eceived clopidogrel and subsequently underwent CABG;
nd 4) among clopidogrel-exposed patients who underwent
ABG, ischemia and bleeding rates were modestly in-
reased in those patients in whom CABG was performed
ithin 5 days after the cessation of clopidogrel.
The ACC/AHA guidelines for the treatment of patients
ith NSTE-ACS recommend upstream therapy with aspi-
in and either clopidogrel or a GP IIb/IIIa inhibitor before
ngiography to reduce ischemic events (1,2). Frequently,
owever, clopidogrel is withheld until after angiography
ecause of concerns about bleeding complications for pa-
ients subsequently referred for CABG. This deviation from
uidelines occurs despite the fact that surgical revascular-
zation in the NSTE-ACS population is required and
erformed in only approximately 10% of patients, poten-
ially disadvantaging the approximately 60% of patients
ndergoing PCI in whom the benefits of early dual anti-
latelet therapy are well established (13,16). Moreover, data
rom the CURE (Clopidogrel in Unstable angina to prevent
ecurrent ischemic Events) trial suggested that patients
ith NSTE-ACS undergoing CABG who received clopi-
ogrel before surgery may in fact have a reduction in adverse
schemic outcomes both before and after surgery compared
ith those undergoing CABG without clopidogrel pre-
reatment (16,17). Before the present study, however, this
bservation had not been confirmed.
In the ACUITY trial, 11.1% of patients with moderate-
nd high-risk NSTE-ACS underwent CABG after diag-
ostic angiography, approximately one-half of whom had
een administered clopidogrel before surgery. To mitigate
ost-operative bleeding, the ACUITY protocol recom-
ended that patients exposed to clopidogrel in whom
ABG was planned wait 5 days if possible before surgical
evascularization, per the current STS and ACC/AHA
uidelines (1,2,12). In the ACUITY trial, with this strategy
pplied to NSTE-ACS patients requiring CABG, pre- aperative administration of clopidogrel was an independent
redictor of freedom from composite ischemia at 30 days,
rimarily because of a significant reduction in the 30-day
ate of MI, consistent with the earlier CURE trial results.
Importantly, patients receiving clopidogrel before CABG
ad comparable rates of post-CABG major bleeding, trans-
usion, and 24-h post-operative chest tube output as those
ho were not exposed to clopidogrel before surgery. This
nding is likely caused by effective contemporary surgical
trategies for minimizing bleeding, as well as delaying
ABG during the index hospitalization in nonurgent cases
hen possible. This practice did result, however, in a longer
edian pre-operative length of stay in patients undergoing
ABG exposed to clopidogrel than for patients not exposed
o clopidogrel (4.2 days vs. 2.5 days, p  0.0001).
Approximately two-thirds of the clopidogrel-exposed
atients underwent CABG within 5 days from the last dose
f clopidogrel, a rate comparable to that from prior reports
6). The lack of adherence to the recommended 5-day
ashout period in the majority of patients likely reflects a
ombination of higher clinical acuity in these patients as
ell as economic imperatives. Regardless of the reasons, it is
eassuring that this practice did not adversely affect net
linical outcomes or adverse ischemic events in the CABG
roup as a whole, but rather was associated with a reduction
n ischemia in the clopidogrel-exposed CABG group com-
ared with those CABG patients who were not exposed to
lopidogrel. The finding that pre-operative clopidogrel ex-
osure reduced adverse composite ischemic events in pa-
ients with NSTE-ACS who required CABG is thus
onsistent with the benefits of this agent in PCI and
edically managed patients with NSTE-ACS. Further
tudy is required to delineate the mechanisms underlying
his effect among CABG patients now seen in 2 large-scale
tudies.
In our study, the overall rates of bleeding were not
ignificantly increased in all CABG patients exposed to
lopidogrel versus those not exposed, or in either the early or
he late CABG groups, although the rate of transfusion was
odestly increased in the clopidogrel-exposed patients un-
ble to wait 5 days for CABG. These findings are also
onsistent with data from the CURE trial, in which the
verall rates of major bleeding were not significantly in-
reased in the CABG patients exposed to clopidogrel before
urgery but were moderately increased (6.3% vs. 9.6%, p 
.06) in patients undergoing surgery within 5 days of
lopidogrel exposure (16,17), and support both the ACC/
HA and STS guidelines for a waiting period after termi-
ation of clopidogrel unless the procedure is urgent/
mergent. Two recent publications also assessed the risk of
leeding in patients exposed to clopidogrel who undergo
ABG (18,19). One analysis of 596 patients described
ignificantly increased bleeding in those exposed to clopi-
ogrel within 5 days of CABG (18), whereas another
nalysis of 4,794 such patients, by far the largest such
nalysis to date, reported no significant increase in major
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xposed to clopidogrel within 5 days of CABG (19).
tudy limitations. The current study is a retrospective
nalysis of an unblinded, nonrandomized subgroup from a
arge, prospective, randomized trial. As such, operators were
ware of the clopidogrel status, and this knowledge may
ave influenced clinical decision making. Specifically, the
roup of clopidogrel-exposed patients who required CABG
ithin 5 days of clopidogrel exposure represent a clinically
igh-risk group, making direct comparison with those
atients able to wait 5 days for CABG problematic. In this
egard, the fact that major bleeding, chest tube output, and
eoperation rates were not significantly increased after
ABG in the early clopidogrel administration group is
eassuring. Intraoperative blood loss was not specifically
uantified. CABG-related outcomes such as chest tube
utput and rates of transfusion were prospectively collected.
owever, these outcomes were not adjudicated by the
linical events committee. In addition, the ACUITY trial
as not powered for the cohort of patients undergoing
ABG or any other patient subgroup; all findings should
hus be considered hypothesis generating. Finally, although
ata regarding clopidogrel use were prospectively collected
n the case report form, the loading dose and exact timing of
he last dose of clopidogrel until the time of CABG in
atients receiving clopidogrel before randomization was not
lways known. Detailed data on clopidogrel use after the
nitial hospitalization were also not available. These limita-
ions are common to previous trials examining the role of
lopidogrel in patients undergoing CABG (6–11,18,19).
onclusions
he findings from the present study support the ACC/
HA guidelines for upstream clopidogrel administration in
ll patients with NSTE-ACS before cardiac catheterization
s part of an invasive management strategy. In the approx-
mately 10% of patients who will require CABG after
oronary arteriography, clopidogrel administration before
urgery is associated with reduced rates of 30-day composite
schemia without significantly increasing post-CABG major
leeding.
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